In the mid to late 1980s, studies were published that provided the first evidence for the existence of glutamate receptors that are not ligand-gated cation channels but are coupled to effector systems through GTP-binding proteins. Since those initial reports, tremendous progress has been made in characterizing these metabotropic glutamate receptors (mGluRs), including cloning and characterization of cDNA that encodes a family of eight mGluR subtypes, several of which have multiple splice variants. Also, tremendous progress has been made in developing new highly selective mGluR agonists and antagonists and toward determining the physiologic roles of the mGluRs in mammalian brain. These findings have exciting implications for drug development and suggest that the mGluRs provide a novel target for development of therepeutic agents that could have a significant impact on neuropharmacology.
INTRODUCTION
Glutamate is the transmitter of the vast majority of the fast excitatory synapses in the mammalian CNS and plays an important role in a wide variety of CNS functions (see 1 for review). Until recently, the actions of glutamate in mammalian brain were thought to be mediated exclusively by activation of glutamate-gated cation channels termed ionotropic glutamate receptors (iGluRs). Modulation of 205 0362-1642/97/0415-0205$08.00 transmission through glutamatergic circuits was thought to require neuromodulators from extrinsic afferents (e.g. dopamine, acetylcholine, serotonin, and norepinephrine) that modulate synaptic transmission and cell excitabiltiy by activating GTP-binding protein (G-protein)-linked receptors. In the mid 1980s, however, evidence for the existence of glutamate receptors directly coupled to second messenger systems via G-proteins began to appear with the discovery of glutamate receptors coupled to activation of phosphoinositide hydrolysis (2, 3). Since that time, it has become clear that glutamate activates a large family of receptors, termed metabotropic glutamate receptors (mGluRs), that are coupled to effector systems through GTP-binding proteins.
The discovery of mGluRs dramatically altered the traditional view of glutamatergic neurotransmission since activation of mGluRs can modulate activity in glutamatergic circuits in a manner previously associated only with neuromodulators from nonglutamatergic afferents. Unlike receptors for monoamines and other neuromodulators, however, the mGluRs provide a mechanism by which glutamate can modulate or fine-tune activity at the same synapses at which it elicits fast synaptic responses. Because of the ubiquitous distribution of glutamatergic synapses, mGluRs have the potential to participate in a wide variety of functions of the CNS. In addition, the wide diversity and heterogeneous distribution of mGluR subtypes provide an opportunity for developing pharmacologic agents that selectively interact with mGluRs involved in only one or a limited number of CNS functions. Thus, gaining a detailed understanding of the specific roles of mGluRs could have a dramatic impact on development of novel treatment strategies for a variety of psychiatric and neurologic disorders.
CLONED mGLURS: CLASSIFICATION

Cloning of mGluRs: Multiplicity Caused by Several Genes and Alternative Splicing
The first mGluR cDNA was cloned independently by two groups that used the same functional expression assay and is now generaly named mGluR1a (4, 5) (see below for the mGluR nomenclature). Its deduced amino acid sequence revealed that this receptor shares no sequence homology with any other G-protein coupled receptor (GPCR), which suggests that it could be a member of a new receptor gene family. Moreover, pharmacologic studies suggested the existence of several G-protein coupled glutamate receptors (6). The search for mGluR-related cDNA has now resulted in the isolation of seven other genes and several splice variants that encode mGluRs (7-17). These receptors are named mGluR1 through mGluR8 ( Figure 1 ).
As mentioned above, splice variants have been found for three mGluRs: mGluR1, mGluR4, and mGluR5 (Figure 2) (7, 8, 14, 16) . All these variants result from the use of alternative acceptor splice sites in an intron whose position is conserved at least between these three genes. mGluR1b, mGluR1c, and mGluR1d lack the long carboxyl-terminal domain specific for mGluR1a. In rat mGluR1b, mGluR1c, and mGluR1d, the carboxyl terminal 318 residues of mGluR1a are replaced by 20 (7), 11 (8) , and 26 (D Stephan & R Pruss, personal communication) residues or 22 residues for human mGluR1d (HmGluR1d) (17) . Compared with mGluR5a, mGluR5b contains an insertion of 32 amino acids, 50 residues after the seventh transmembrane domain (TMD) (13, 14) . The carboxyl-terminal 63 residues of mGluR4a are replaced by 136 residues in mGluR4b (16) .
To date, the human homologues of mGluR1a, b, and d (17, 18) , mGluR2 (19), mGluR3 (20), mGluR4a (21), mGluR5a and b (14, 22 ) have been cloned. The primary sequence of the human receptors show 93-96% identity compared with the rat homologues. A metabotropic glutamate receptor called DmGluRA has also been cloned from Drosophila melanogaster (22a). It shows a high homology with the mammalian group II mGluRs (45% identity of the amino acid sequence with mGluR3) (Figure 1 ).
Based on their amino acid sequence identity, the eight mGluRs can be classified into three groups (Figure 1 ) (23). mGluRs of the same group show about 70% sequence identity, whereas between groups this percentage decreases to about 45%. Group I includes mGluR1 and mGluR5; group II, mGluR2 and mGluR3; and group III, all others. The Drosophila receptor DmGluRA is more related to group II mammalian mGluRs (Figure 1 ).
These receptors are much larger than all previously identified GPCRs and do not share any sequence homology with members of that gene superfamily. mGluRs therefore define a new family of GPCRs. Three years ago, a Ca 2+ -sensing receptor (CaR) cDNA was isolated from a bovine parathyroid cDNA library. It has a surprisingly high homology (30% sequence identity) with mGluRs (24). This receptor is not sensitive to mGluR agonists but is sensitive to other cations, such as Mg 2+ , Gd 3+ , and to neomycin. The rat and human homologues of CaR have been cloned and display 92 and 93% identity with the bovine receptor (25-27). This indicates that this new family of GPCR is not restricted to glutamate receptors and may include additional members sensitive to other ions or transmitters.
Transduction Mechanisms of mGluRs Expressed in Heterologous Systems
As already presented, mGluRs can be subdivided into three groups based on the homology of their amino acid sequences. This classification is also supported by the respective transduction mechanisms of the different mGluR subtypes (Figure 1 ).
In every expression system examined, group I mGluRs, including their splice variants, stimulate phospholipase C and phosphoinositide (PI) hydrolysis (4, 5, 8, 9, 13, 14, 17, 18, 22) . Coupling of mGluR1a to ion channels has also been examined after injection of its cRNA into superior cervical ganglion neurons, where this receptor can inhibit M-type K + channels (28). It is not clear, however, whether this is mediated by direct coupling through a G-protein to the M-type channel or is secondary to activation of phosphoinositide hydrolysis. Stimulation of cAMP formation has also been reported for mGluR1a in several cell types (13, (29) (30) (31) . A similar effect of mGluR5a and mGluR5b has also been reported in LLC-PK1 cells (13) but not in CHO cells (9). Although a direct coupling to adenylyl cyclase (AC) through G S -protein is likely (32), this has not been definitively demonstrated. Moreover, whether this is an heterologous coupling caused by the expression of these receptors at high levels in non-neuronal cells or is reminiscent of a low G-protein selectivity of these receptors that is also true in neurons remains to be elucidated.
As described above, alternative splicing of group I mGluR pre-mRNA generates receptors with different intracellular carboxyl-terminal domains. When expressed into mammalian cells, no functional differences between mGluR5a and mGluR5b were noticed (13, 14) . However, a role of the mGluR5b cassette in controlling G-protein coupling specificity has been proposed (14) . Functional differences have been reported between the mGluR1a variant that possesses the long carboxyl-terminal intracellular tail and the truncated isoforms mGluR1b and mGluR1c. Compared with the short receptors, mGluR1a generates faster responses in Xenopus oocytes (8), can activate AC (13, 30, 31) , and is slightly active even in the absence of agonist (33). Two explanations can be proposed for these functional differences. Either the differences are caused by a difference in the level of expression of these different receptors in these heterologous expression systems, mGluR1a being expressed at a higher level than the short receptors mGluR1b or mGluR1c, or they are caused by a difference in the coupling efficiency of these receptors to the G-proteins. Estimation of the level of expression of the different variants by Western blot and immunofluorescence, along with indirect functional evidence, suggests that the long carboxyl-terminal domain of mGluR1a increases the coupling efficiency of the receptor (8, 33).
When expressed in mammalian cells, group II mGluRs (mGluR2, mGluR3, and the Drosophila homologue DmGluRA) inhibit cAMP formation stimulated by either forskolin or a G S -coupled receptor (7, 22a, 34). This effect is inhibited by pertussis toxin (PTX) treatment of the cells, which indicates the involvement of a G i -type of G-protein. Inhibition of N-type Ca 2+ channels through a PTXsensitive pathway by mGluR2 has also been demonstrated after expression of this receptor in superior cervical ganglion neurons (28) or HEK-293 cells that stably express the N-type Ca 2+ channels (human α1B-1, α2b, and β1-3 subunits) (35). Like mGluR2, mGluR3 inhibits N-type Ca 2+ channels in these HEK 293 cells (35).
Like group II mGluRs, all group III mGluRs inhibit adenylyl cyclase via a PTX-sensitive G-protein when expressed in CHO or BHK cells (10-12, 15, 34). The inhibition observed, however, is often smaller than that obtained with group II mGluRs, which suggests either that group III mGluRs are not expressed at very high density in the plasma membrane of these cell lines or that this is not the preferred transduction pathway of these receptors. The second hypothesis seems likely because mGluR6 is likely to couple to a cGMP phosphoidiesterase in its native environment (36; see below). Moreover, coupling of mGluR7 to heterogenously expressed G-protein-activated inwardly rectifying potassium channel has been reported in Xenopus oocytes (37).
Pharmacology of Cloned mGluRs
Glutamate is a very flexible molecule that can adopt different conformations. Several derivatives of glutamate, including rigid analogues, have therefore been synthesized with the hope of discriminating among the different glutamate receptors. To date, there are several molecules that can be used to activate or antagonize mGluRs of the different groups specifically (Figure 1) . In this chapter, we review our actual knowledge of the pharmacology of typical members of each mGluR group (mGluR1, mGluR2, and mGluR4, respectively) and describe the pharmacologic differences among members in each group. We have concentrated on the pharmacology of cloned mGluRs expressed in heterologous systems, because this is the only way to characterize the activity of compounds on a specific mGluR subtype. Not only may several mGluRs be involved in a response observed in the brain, it is not likely that all the mGluRs have already been cloned. We use this information to try to identify the mGluR subtypes involved in a given physiologic response. Focusing on cloned receptors expressed in heterologous systems has, however, two main disadvantages. First, the potencies measured in these expression systems may not necessarily be identical to those in the native environment of the receptor. Second, many new promising compounds that have been recently described are not presented here because their actions on cloned receptors have not been reported (38-40).
GROUP I mGLURs The pharmacologic profile of group I mGluRs has been primarily studied with the use of mGluR1a as a prototypic member. Several agonists have been characterized, and their rank order of potency is as follows: quisqualate >3, 5-dihydroxyphenylglycine (3, 5-DHPG) glutamate >1S, 3R-1-amino-1, 3-cyclopentanedicarboxylate (ACPD) = ibotenate > (2S, 1'S, 2'S)-2-(carboxycyclopropyl)glycine (L-CCG-I) > 3-hydroxyphenylglycine (3-HPG) > trans-azetidine-2, 4-dicarboxylate (t-ADA) (Table 1 and Figure 3 ). Among these 3, 5-DHPG, 3-HPG, and t-ADA are specific agonists (although n.e. -500 (11, 12, 46) , mGluR8 (15) . n.e., no effect; -, not determined. less efficient than glutamate), as they have almost no effect on ionotropic receptors or on mGluR2 and mGluR4 (41-46). However, t-ADA has been reported to have no effect on HmGluR1b and HmGluR5a (47) and has been described as inactive on mGluR1a by others (42). Other agonists of mGluR1a are (2S, 1 R, 2 R)-2-(carboxycyclopropyl)glycine (L-CCG-II) (EC50 = 200 µM), homocysteate (HCA; partial agonist), homocysteine sulfinate (HCSA: EC50 = 300 µM) and the neurotoxin β-N-methylamino-L-alanine (BMAA; EC50 = 480 µM) (29, 48-50). The first antagonist described for mGluR1a was α-methyl-4-carboxyphenylglycine (MCPG). Several derivatives of phenylglycine have since been synthesized, and (S)-4-carboxyphenylglycine ((S)-4CPG) and (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) were found to be the most potent competitive antagonists of this receptor (50) (51) (52) . More recently, new compounds with original structures were found to be even more potent than these phenylglycine derivatives on mGluR1a but inactive on mGluR2 and mGluR4. These include 1-aminoindan-1, 5-dicarboxylate (AIDC) (53) and 7-(hydroxyimino) cyclopropa [b] chromen-1a-N,N-methyl, phenyl-carboxamide (7HCCMA) (54) (Figure 3 ). Bromohomoibotenate (BrHIBO) has also been described as another specific competitive antagonist of mGluR1a with a low potency, inactive on mGluR2 and mGluR4 (55) . Another antagonist of mGluR1a is (1RS, 2SR, 4RS, 7RS)-amino-bicyclo[2.2.1]heptane-dicarboxylate (ABHD-I), a rigid analogue of ACPD (56) . Although it has a low potency (300 µM), this compound is interesting because of its totally rigid structure so that the relative positions of the carboxyl and amino groups in the binding site are the same as in solution and are perfectly known.
The pharmacologic profiles of the short mGluR1 variants (mGluR1b and mGluR1c) are identical to those of mGluR1a. In many cases, EC 50 values for the short receptors are higher than those for the long form (30, 33, 57), either because of a better expression or because of a better coupling efficiency of mGluR1a resulting from the presence of the long carboxyl-terminal tail (57; see above). The agonist rank order of potency of mGluR5a and b is similar to that of mGluR1a; most agonists, other than glutamate, are three to ten times more potent (9, 13). However, both rat and human mGluR5a, although antagonized by MCPG, are much less sensitive to 4CPG and 4C3HPG than is mGluR1a (43, 58). These latter compounds may therefore be useful for discriminating between mGluR1-and mGluR5-mediated responses.
GROUP II mGLURs The agonist rank order of potency at the prototypic member of group II mGluRs, mGluR2 is ( (Table 1 and Figure 3 ). Among these, only 2R, 4R-APDC is a specific group II agonist (although its effect on mGluR3 has not been reported yet) (59), because DCG-IV is an agonist of N-methyl-D-aspartate (NMDA) receptors (60); L-CCG-I is also active on mGluR1 and mGluR4, although with a tenfold lower potency (44, 48). 1S, 3S-ACPD, which has been widely used as a specific group II mGluR agonist, is also active on mGluR4, although with a lower potency (44). In addition, 1S, 3S-ACPD induces PI hydrolysis and elicits electrophysiologic responses thought to be mediated by group I mGluRs in hippocampal slices (46, 61) . This compound should therefore not be used as a group II selective agonist. The group II mGluR agonist 4C3HPG is a very useful compound because of its antagonist action on mGluR1 and its lack of effect on mGluR4 (50) (51) (52) 62) . Several competitive antagonists for mGluR2 have been reported. After the discovery of the antagonist action of MCPG, several other phenylglycine derivatives were found to be competitive antagonists of this receptor. Their rank order of potency is α-methyl-4-phosphonophenylglycine (MPPG) > α-methyl-4-sulfonophenylglycine (MSPG) > α-methyl-4-tetrazoylphenylglycine (MTPG) (44, 63). More potent competitive and specific antagonists include α-methyl-L-CCG-I (MCCG-I) (44), 2S, 4S-2-amino-4-(4, 4-diphenylbut-1-yl)-pentane-1, 5-dioic acid (ADPD) (64) and (2S, 1 S, 2 S, 3 R)-2-(2 -carboxy-3 -phenylcyclopropyl) glycine (PCCG-IV) (63), the latter being the most potent antagonist described so far for mGluR2 (Table 1 and Figure 3 ).
The pharmacology of mGluR3 is less well characterized but seems to be very similar to that of mGluR2 (34, 65); the main difference is that quisqualate, which is almost devoid of effect on mGluR2 (7, 19, 44), is relatively potent on mGluR3 (34). Little is known about the antagonist pharmacology of mGluR3. By measuring inhibition of N-type Ca-channels in HEK-293 cells, McCool and colleagues (35) reported that MCPG is far less potent and that MCCG-I is more potent on mGluR3 than on mGluR2. Taken together, these observations indicate that it is possible to discriminate between responses mediated by mGluR2 and mGluR3 and that more selective drugs able to discriminate between these two receptors can be synthesized.
GROUP III mGLURs The pharmacology of mGluR4 is very different from that of the other mGluRs. The rank order of potency of several agonists is
1S, 3R-ACPD (Table 1 and Figure 3 ). L-AP4 and L-SOP are very specific for group III mGluRs, as they are inactive on any other glutamate receptors. Several other L-AP4 derivatives have been described as agonists of mGluR4, including Z-cyclopropyl-AP4 (Z-CPAP4), which is as potent as L-AP4 (66) (Figure 3 ). Most mGluR1 and mGluR2 antagonists are inactive on mGluR4, except MPPG, which appears to be slightly more potent on mGluR4 than on mGluR2 (44, 63). α-methyl-L-amino-4-phosphonobutyrate (MAP4) appears the more selective mGluR4 antagonist; however, it is also an antagonist with low potency on mGluR2 (44, 67) ( Figure 3 ).
The pharmacology of the other group III mGluRs has been poorly characterized; however, all are clearly activated by L-AP4 (10) (11) (12) 15) . Surprisingly, the agonist potencies on mGluR7 are very low, being almost 1000 times lower than those determined on mGluR4 (11, 12) . Whether this is because of the expression of this receptor subtype in heterologous cells or is also true in neurons remains to be elucidated. However, very high concentrations of L-AP4 are required to inhibit AC in some neurons maintained in culture (68) . In addition, high concentrations of L-AP4 are required for activation of some mGluR autoreceptors (see below).
STRUCTURE AND FUNCTIONAL DOMAINS OF CLONED MGLURS
General Structure
As mentioned previously, mGluRs and CaR share no sequence homology with any other GPCRs. They all possess a surprisingly large N-terminal ex- tracellular domain, seven putative TMDs separated by short intra-and extracellular loops, and a cytoplasmic carboxyl-terminal domain variable in length (Figure 4) . Nineteen cysteine residues located in the predicted extracellular domain and extracellular loops are conserved in all members of this receptor family, which suggests important roles for these residues either in the threedimensional structure of the molecule or in the intramolecular transduction. Accordingly, a high sensitivity of glutamate-stimulated PI turnover to reducing agents has been reported (69) .
The Glutamate Binding Site
Whereas the agonist binding site for small ligands in most GPCRs is located in a pocket formed by the seven transmembrane domain segments (70), this is not the case in mGluRs. O'Hara and co-workers (71) noticed a weak sequence similarity of the extracellular domain of mGluRs with bacterial periplasmic binding proteins (PBP), especially with the leucine, isoleucine, valine binding protein (LIVBP). This homology was therefore used to construct a model based on the reported three-dimensional structures of several PBPs. This model predicts that the extracellular domain of mGluRs is made up of two globular domains with a hinge region (Figure 4) . The glutamate binding site is proposed to be equivalent to the known amino acid binding sites of PBPs. This model allowed the identification of two residues, S165 and T188, in the extracellular domain of mGluR1, mutation of which affects glutamate affinity (71) . This model is also supported by the construction of chimeric receptors that exchange the LIVBP-like domain between two mGluRs with different pharmacology (72, 73) . It is noteworthy that loss-of-function mutations were identified in close proximity of the hinge region of the parathyroid CaR in patients who had genetic diseases that affected Ca 2+ homeostasis (74, 75) . Finally, this model received indirect confirmation from work on the glutamate receptor channel subunits. The same computational analysis revealed that these receptor subunits possess two domains homologous to PBP, one homologous to LIVBP, and one homologous to lysine, arginine, ornithine binding protein (LAOBP) (71) . Recently, an analysis of mutated NMDA-R1 subunit and chimeric α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA)/kainate receptor subunits revealed that the LAOPB domain is likely involved in the agonist binding (76, 77) . Moreover, production of the LAOBP-like domain of the AMPA receptor subunit GluR4 as a soluble protein in insect cells revealed that this domain can bind glutamate and has the same pharmacologic profile as the native subunit (78) . All glutamate receptors may therefore share a similar structure for their agonist recognition domain.
G-Protein Coupling
The regions involved in the activation of G-proteins by the other GPCRs have been extensively studied (70, 79) . The DRY (or ERW) tripeptide found at the N-terminal end of the second intracellular loop of most GPCRs has been shown to play an important role in the coupling to and activation of the G-proteins. Moreover, cysteine residues located downstream of the seventh TMD are often palmitoylated and are therefore likely anchored to the plasma membrane (80) . This generates a fourth intracellular loop, which is sometimes necessary for the correct coupling to G-protein (80) . Finally, the third intracellular loop of most GPCRs plays a critical role in the G-protein coupling specificity. Both its N-and C-terminal ends are supposed to fold into amphipathic α helices that extend toward the cytoplasm TM5 and 6, respectively (81) . It has recently been reported that the C-terminal end of the muscarinic receptor directly interacts with the C-terminal end of the α subunit of the G-protein (82) .
In mGluRs, the DRY signature is absent in any intracellular loops, a cysteine residue has been shown to be palmytoylated in mGluR4 but not in mGluR1a (83) , and the sequence of the third intracellular loop (i3) is conserved in all members of this receptor family, thereby making it unlikely to play an key role in G-protein coupling selectivity. By constructing chimeras between the PLC-coupled mGluR1 and the AC-coupled mGluR3, it has been shown that the second intracellular loop (i2) of mGluRs plays a critical role in G-protein coupling specificity (65, 84, 85) (Figure 4 ) and that, as described for the other GPCRs, all intracellular segments are indeed involved in the coupling and activation of the G-protein, apparently controling the coupling efficacy (84) . In agreement with the involvement of i3 in G-protein coupling, a mutation in this loop of the human CaR1 that prevents the receptor from activating PLC has been found in familial hypocalciuric hypercalcemia patients (74) . Interestingly, i2 of mGluRs likely possesses amphipathic α helices that extend TM3 and 4 toward the cytoplasm (65) and is likely to interact directly with the carboxylterminal end of the G-protein α subunit (85) . Taken together, these results strongly suggest that i2 of mGluRs plays a role equivalent to that of i3 of the other GPCRs.
The role of the large intracellular C-terminal domain of mGluR1a and mGluR5a and b is not known. As discussed earlier, this domain likely facilitates the coupling of the receptor to the G-protein (8, 30, 31, 33 ). However, this may not be the main role of these 300 amino acid residues. These residues may be involved in the specific targeting of these receptors to specific compartments in neurons (see 86) . In addition, the presence of multiple serine and threonine residues that could constitute the target for GPCR kinases, several putative protein kinase (including MAP kinase) phosphorylation sites (87) , and SH3 binding sites strongly suggests that this domain is involved in the regulation of the receptor. This will be a direction for intense investigation in the coming years.
Intramolecular Transduction
As described above, the glutamate binding site is located in the large extracellular domain, and the G-protein coupling region corresponds to the intracellular loops separating the TMDs. It remains now to understand how the binding of glutamate in the LIVBP-like domain induces the conformational changes in the intracellular loops required for the activation of the G-protein.
The mode of action of PBPs has been extensively studied (88) . It may help in proposing different hypotheses for the intramolecular transduction in mGluRs. PBPs are periplasmic proteins involved in the the high-affinity transport of amino acids, carbohydrates, and ions into the bacterial cytoplasm. As mentioned above, PBPs are composed of two lobes separted by a hinge region where the ligand binds. On ligand binding, the two lobes close like a clamshell; the liganded, closed PBP interacts with a complex of two transmembrane proteins. The ligand is then delivered to the transmembrane proteins that will carry it into the cytoplasm, thanks to the activity of an associated cytoplasmic ATPase (88) . By analogy with this mode of action of PBPs, and considering that most ligands interact within a cavity formed by the 7TMD in GPCRs, the LIVBP-like domain of mGluRs may simply serve to trap glutamate and then deliver it to another site located in the 7TMD. An alternative hypothesis is that the big change in conformation in the LIVBP-like domain associated with its closure will be transduced to the 7TMD thanks to the cysteine-rich region. (97, 98) reported evidence for a phosphoinositide hydrolysis-coupled mGluR in cortical slices that does not correspond to any of the previously cloned mGluR subtypes. This receptor is insensitive to 1S, 3R-ACPD but is selectively activated by BrHIBO or (R, S)4-methylhomoibotenic acid. Earlier studies that suggested the existence of multiple mGluR subtypes coupled to activation of phosphoinositide hydrolysis in native tissues have been discussed in previous reviews (6, 89)
REGULATION OF SECOND MESSENGERS BY MGLURS IN NATIVE SYSTEMS
Phosphoinositide Hydrolysis as a Transduction
System for mGluRs mGluRs couple to activation of phosphoinositide hydrolysis in a number of native preparations, including cultured astrocytes, cultured neurons, synaptoneurosomes, and brain slices (see 89 for review). As would be predicted from studies in expression systems, evidence suggests that most mGluR-mediated phosphoinositide hydrolysis responses in brain slices and cultured cells are mediated by group I mGluRs (46, 90-94) but not group II (95) or group III (96) mGluRs. Evidence suggests, however, that novel mGluRs may also exist that couple to phosphoinositide hydrolysis. For instance, Chung et al
Coupling of mGluRs to Changes in cAMP Accumulation
INHIBITION OF ADENYLYL CYCLASE Consistent with studies in expression systems, a number of studies suggest that activation of group II (59, 68, 99, 100) and group III (40, 68, 100, 101) mGluRs inhibits forskolin-induced increases in cAMP accumulation in brain slices and neuronal cultures, whereas group I mGluRs do not (91) . In most studies, however, mGluR-mediated inhibition of the cAMP response to the adenylyl cyclase activator forskolin has been measured, rather than responses to agonists of receptors that activate adenylyl cyclase via coupling to G S . It is therefore not clear whether each of the group II and group III mGluRs actually couple to inhibition of neurotransmitter-induced increases in cAMP accumulation in native systems. Indeed, as discussed below, activation of group II mGluRs potentiates, rather than inhibits, increases in cAMP accumulation induced by receptor agonists in adult hippocampal slices (102) , which suggests that group II mGluRs have the opposite effect when physiologically relevant agonists are used. In contrast, L-AP4 and L-SOP have been shown to inhibit agonist-induced increases in cAMP accumulation in hippocampal slices (99) , which suggests that group III mGluRs do couple to inhibition of G S -activated adenylyl cyclase in this region.
INCREASES IN CYCLIC AMP ACCUMULATION There is little compelling evidence to suggest the presence of an mGluR that is positively coupled to adenylyl cyclase via G S in native preparations. However, mGluR activation potentiates cAMP responses to agonists of other receptors that couple G S , including vasoactive intestinal polypeptide, 2-chloroadenosine (2-CA), the β-adrenegic receptor agonist isoproterenol, and prostaglandin E2 (103, 104) . Activation of mGluRs increases basal cAMP accumulation in hippocampal slices by potentiating cAMP responses to adenosine that is already present in the extracellular space (104) . Interestingly, both group I and group II mGluRs can be involved in potentiating cAMP responses, and the relative contributions of these different mGluR subtypes depends on the tissue being studied. In adult rat hippocampus, group II mGluR agonists potentiate cAMP responses to agonists of G S -coupled receptors, whereas agonists of group I and group III mGluRs are without effect (102) . In contrast, agonists of group I and group II mGluRs synergistically potentiate cAMP responses in hippocampus from young animals (105).
Activation of mGluRs Increases Cyclic GMP Accumulation
Okada (106) reported that mGluR activation increases cGMP levels in cerebellar slices and that this response can be blocked by inhibitors of nitric oxide (NO) synthase. This suggests that the cGMP response to mGluR activation depends on formation of NO, which can directly activate guanylyl cyclase. At present, the mGluR subtype that mediates this increase in cGMP in cerebellum is unknown, although mGluR1 is a strong candidate. Physiologic studies suggest that mGluR activation may also increase cGMP accumulation in the rat nucleus tractus solitarius (NTS). In this region, mGluR activation has a number of physiologic effects that can be mimicked by activators of guanylyl cyclase (107) . These responses are not altered by manipulations that increase or decrease NO levels but can be blocked by a selective inhibitor of heme oxygenase, an enzyme involved in CO synthesis. In contrast, this heme oxygenase inhibitor did not block the effects of a cell permeable cGMP analogue. Based on these findings, it has been proposed that mGluR activation regulates certain aspects of cell excitability and synaptic transmission in the NTS by a mechanism that depends on CO-induced activation of guanylyl cyclase.
Interestingly, evidence suggests that activation of a group III mGluR in retinal ON bipolar cells reduces cGMP accumulation. In these cells, glutamate, or selective group III mGluR agonists, induces a hyperpolarization that is mediated by reduction of a cGMP-activated cation current that is tonically active (36, 108). This response is probably mediated by coupling of the mGluR to a cGMP phosphodiesterase and a subsequent reduction in cGMP levels. In situ hybridization studies suggest that mGluR6 is a likely candidate for the mGluR subtype that mediates this response (10, 109), although mGluR8 could also be involved (15) .
Coactivation of mGluRs and AMPA Receptors Increases Arachidonic Acid Release
Evidence suggests that activation of mGluRs results in increased phospholipase A2 (PLA2) activity in cortical neuron-glia cultures (110) and that increases in arachidonic acid (AA) release in cortical astrocytes (111) . This response has been proposed to play a role in glial-neuronal signaling by inhibiting activity of astrocytic glutamate transporter proteins. Coactivation of mGluRs and α-amino-3-hydroxyl-5-methyl-1-isoxazole-4-propionic acid (AMPA) receptors also induces a dramatic PLA2-dependent increase in AA release in striatal neurons (112) . At present, the mGluR subtypes that lead to increases in AA release are not known. However, the increase in AA release in striatal neurons can be elicited by quisqualate, which suggests the possibility of mediation by a group I mGluR.
A Novel Metabotropic Receptor Coupled to Activation of Phospholipase D
Recent studies suggest that a novel metabotropic receptor exists in hippocampal slices that is coupled to activation of phospholipase D (PLD) (113, 114) . Interestingly, the pharmacologic profile of the PLD-coupled receptor is consistent with its being an mGluR but is not consistent with that of any of the mGluR subtypes that have been cloned to date (113) . Further, L-cysteine-sulfinic acid (L-CSA) is more efficacious than glutamate at activating this receptor (113) , which suggests that L-CSA may serve as an endogenous agonist of this receptor.
ROLES OF mGLURS IN REGULATING ION CHANNELS AND CELL EXCITABILITY
Modulation of Potassium Channels and Nonselective Cation Currents
Activation of mGluRs by stimulation of glutamatergic afferents or exogenous application of mGluR agonists results in widespread and diverse actions on neuronal excitability by modulation of a variety of voltage-dependent and voltageindependent ion channels. A comprehensive treatment of the regulation of ion channels by mGluRs is beyond the scope of this review but has previously been reviewed in detail (115, 116) . Potassium channels are among the most common targets for modulation by mGluRs. For instance, in hippocampal pyramidal cells, activation of mGluRs results in a reduction in a leak potassium conductance (I leak ) (117), the calcium-dependent slow afterhyperpolarization current (I AHP ) (118, 119) , a slow noninactivating voltage-dependent potassium current termed I M (118) , and a slowly inactivating voltage-dependent current termed I K(slow) (120) . These combined actions of mGluR activation result in a dramatic increase in cell excitability. Evidence suggests that group I mGluRs are the predominant mGluRs involved in increasing excitability of hippocampal CA1 pyramidal cells (46, 121) . mGluRs can also exert direct excitatory effects on neurons by activation of nonselective cation currents (122) (123) (124) (125) (126) (127) (128) (129) (130) . The exact mechanisms involved in generation of the cation currents likely vary in different cell types but can include activation of a Na + /Ca 2+ exchanger (124, 128) , activation of a Ca 2+ -activated nonspecific cation (CAN) current (125) , and activation of a calcium-independent nonspecific cation channel (127) . Interestingly, the mGluR agonist-induced cation conductance in CA3 pyramidal cells and dorsolateral septal nucleus neurons may not be dependent on activation of G-proteins (126, 129) , which raises the exciting possibilty that mGluRs may couple to cation channels by a GTP-binding protein-independent mechanism. Alternatively, mGluR agonists may activate a novel ionotropic glutamate receptor that has a binding site more closely related to that of the mGluRs than to that of other ionotropic glutamate receptors.
mGluR activation can also exert direct inhibitory effects on neurons. For instance, mGluR activation induces a hyperpolarization of basolateral amygdala neurons that is likely mediated by opening of potassium channels (131) . This response can be elicited by RS-4C3HPG, which is an agonist at group II mGluRs and an antagonist at group I mGluRs and has no effect at group III mGluRs (52) . Further, as discussed above, activation of a group III mGluR induces a marked hyperpolarization of retinal ON bipolar cells (36, 108).
Modulation of Voltage-Dependent Calcium Channels
A number of studies suggest that mGluR activation can decrease currents through voltage-dependent calcium channels. mGluR activation reduces L-type, but not N-type, calcium currents in acutely isolated neurocortical neurons (132) . In addition, it reduces N-type, but not L-type, currents in CA3 pyramidal cells (133) , striatal neurons (134), cultured retinal ganglion neurons (135) , and neurons in cortical slices (136) . In cultured cortical (137) and cerebellar (138) neurons, mGluR activation reduces both N-and L-type calcium currents. The mGluR subtype involved in regulating calcium channels also varies depending on the cell type. Inhibition of N-type calcium currents in cortical neurons is likely mediated by both group I and group II mGluRs, whereas group III-selective agonists are without effect (136) . The pharmacologic profile of inhibition of N-type calcium currents in cultured granule cells is consistent with mediation by group II but not group I or III mGluRs (138) . In olfactory bulb (139) , retinal ganglion (135) , and a subpopulation of hippocampal neurons (133, 137) , L-AP4 is effective in inhibiting calcium currents, which suggests that group III mGluRs may also modulate calcium currents in some cell types.
Activation of mGluRs has been reported to increase N-type calcium currents in retinal ganglion neurons (135) and L-type calcium currents in cerebellar granule cells (138, 140) . In both cell types, the receptor that mediates this response has a pharmacologic profile consistent with a group I mGluR. Both mGluR1 and mGluR5 are expressed in cerebellar granule cells (141) .
REGULATION OF SYNAPTIC TRANSMISSION BY mGLURS mGluRs Serve as Presynaptic Autoreceptors at Glutamatergic Synapses
One of the most prominent physiologic effects of mGluR agonists that is consistent throughout the CNS is reduction of transmission at glutamatergic synapses. This effect is typically mediated by presynaptic mGluRs that serve as autoreceptors to reduce glutamate release (see 142 for extensive review).
HETEROGENEITY OF mGLUR AUTORECEPTORS In recent years, it has become clear that multiple mGluR subtypes, which belong to each of the three major groups, can serve as autoreceptors. In adult hippocampal area CA1, group I and group III mGluRs serve as autoreceptors, whereas group II mGluRs do not (143, 144) . Pharmacologic and immunocytochemical studies suggest that mGluR5 (144, 145) and mGluR7 (143, 146) are the most likely group I and group III mGluRs to serve as autoreceptors at this synapse, respectively. Interestingly, the pharmacology of mGluR autoreceptors in neonatal area CA1 differs from that in adults (147, 148) , which suggests that there may be a developmental regulation of the mGluR subtypes that serve as autoreceptors in this region.
At the lateral perforant path-dentate gyrus synapse, a group III mGluR that is pharmacologically different from the group III mGluR at the adult Schaffer collateral-CA1 synapse serves as an autoreceptor (66, (149) (150) (151) . There is no involvement of group I or group II mGluRs as autoreceptors at this synapse. At the medial perforant path synapse, a group II mGluR serves as an autoreceptor (151, 152) , whereas there is no effect of group I-selective agonists. L-AP4 reduces transmission at the medial perforant path synapse with low potency, which is consistent with the possibility of a role of mGluR7 (151, 153) . Consistent with this, there is heavy localization of mGluR7 immunoreactivity in the middle third of the molecular layer of the dentate gyrus, where medial perforant path afferents terminate (146) .
Both group II and group III mGluRs serve as autoreceptors at the guinea pig mossy fiber-CA3 synapse (154) and in the spinal cord (155, 156) . At corticostriatal synapses, a group II mGluR serves as an autoreceptor, whereas there is no effect of group III mGluR activation (157) . The pharmacologic profiles of mGluR autoreceptors at other synapses have not been rigorously examined, although group III mGluR agonists have been shown to reduce transmission at several other glutamatergic synapses, including synapses in the olfactory cortex, amygdala, neocortex, and olfactory bulb (see 142 for review).
MULTIPLE MECHANISMS OF REGULATION OF GLUTAMATE RELEASE The mechanisms by which mGluR activation reduces glutamate release from presynaptic terminals are not known. Reduction of voltage-dependent calcium currents, as described above, probably provides at least one mechanism by which mGluR activation can reduce glutamate release. Activation of some mGluRs, however, may reduce glutamate release by mechanisms that are not dependent on regulation of voltage-dependent calcium channels. For instance, L-AP4 induces a marked reduction in miniature excitatory postsynaptic current (mEPSC) frequency in hippocampal CA1 pyramidal cells (143) . In contrast, the nonselective calcium channel blocker cadmium abolishes evoked EPSCs in this region but has no effect on mEPSCs (143) . Similar results have been reported within hippocampal area CA3 (158) and in corticostriatal co-cultures (159) . These data suggest that L-AP4 must reduce mEPSC frequency by a mechanism that is independent of modulation of voltage-dependent calcium channels. In contrast, the group I-selective agonist DHPG reduces transmission in area CA1 but has no effect on either frequency of amplitude of mEPSCs (143) . These data suggest that group I and group III mGluRs reduce EPSCs in area CA1 by different mechanisms.
Another possible mechanism of mGluR autoreceptor function is activation of presynaptic potassium currents. Sladeczek et al (160) reported that 1S, 3R-ACPD reduces transmission at excitatory synapses in visual cortex and found that this effect was inhibited by the potassium channel blocker 4-aminopyridine (4-AP), which raises the possibility that mGluR activation reduces EPSCs by a mechanism involving 4-AP-sensitive channels.
Coactivation of Group II mGluRs and β-Adrenergic Receptors on Glia Can Reduce Glutamate Release Through a Novel Form of Glial-Neuronal Communication
Recent studies have revealed a novel mechanism by which mGluR activation can reduce transmission at glutamatergic synapses. As discussed above, activation of group II mGluRs in adult hippocampal slices results in a marked potentiation of the cAMP response to the β-adrenergic receptor agonist isoproterenol (102, 104, 161) . Evidence suggests that the large increase in cAMP accumulation that occurs in response to coactivation of group II mGluRs and β-adrenergic receptors results in release of cAMP or a cAMP metabolite, such as adenosine, from the cells of synthesis (162) . This leads to activation of presynaptic A 1 adenosine receptors on Schaffer collateral terminals and results in a marked reduction of transmission at the Schaffer collateral-CA1 synapse. Interestingly, the synergistic increase in cAMP accumulation that leads to this response occurs in glia rather than in neurons (161) . Thus, group II mGluRs (likely mGluR3) localized on glia are involved in a novel form of glial-neuronal communication that could play an important role in regulating excitatory synaptic transmission in the hippocampus during periods in which noradrenergic inputs to the hippocampus are active.
mGluR Activation Can Lead to an Increase in Glutamate Release
Under certain conditions, mGluR activation can increase, rather than decrease, glutamate release. For instance, activation of mGluRs in cortical synaptosomes in the presence of arachidonic acid results in an increase in 4-aminopyridineinduced glutamate release (163) . Further, coapplication of trans-ACPD and arachidonic acid to hippocampal slices results in a lasting potentiation of evoked excitatory postsynaptic potentials (EPSPs) at the Schaffer collateral-CA1 synapse (164) . Thus, the potentiation of glutamate release that occurs when mGluRs are activated in the presence of arachidonic acid is sufficient to overcome the autoreceptor-mediated depression of transmission at this synapse.
mGluRs Serve as Presynaptic Heteroceptors at GABA Synapses
Presynaptic mGluRs have been shown to reduce GABA release and inhibitory synaptic transmission in several brain regions (60, 143, (165) (166) (167) . As with the presynaptic autoreceptors, evidence suggests that members of each major group of mGluRs can serve as presynaptic heteroceptors on GABAergic terminals. In addition, group II mGluRs reduce transmission at inhibitory synapses in the accessory olfactory bulb (60), hippocampal area CA3 in young animals (167) , and thalamus (165), whereas group I mGluRs reduce GABA release from presynaptic terminals in area CA1 of the hippocampus of adult rats (143) . Both group II and group III mGluRs can serve this role in the thalamus (165) .
mGluR-induced Modulation of Ligand-Gated Ion Channels
In addition to regulating glutamate and GABA release, mGluRs can regulate both excitatory and inhibitory transmission by modulating currents through glutamate and GABA receptor channels. In contrast to regulation of neurotransmitter release, mGluR-mediated modulation of ligand-gated ion channels allows selective modulation of specific components of synaptic potentials. For instance, activation of mGluRs enhances NMDA receptor-mediated responses without modulating responses to activation of non-NMDA ionotropic glutamate receptors in some neuronal populations (168) (169) (170) (171) . In hippocampal neurons, this effect appears to be mediated by a group I mGluR (169) .
In spinal cord dorsal horn neurons, mGluR activation potentiates currents through both NMDA and non-NMDA glutamate receptors (172, 173) . In the NTS, mGluR activation reversibly potentiates AMPA-evoked currents and depresses currents through GABA A receptors (122) . Interestingly, mGluR activation reduces NMDA-evoked depolarizations in striatal neurons (174) . The impact of mGluR activation on ligand-gated ion channels is therefore highly variable in different cell populations and is likely to play unique roles in regulating inhibitory and excitatory synaptic transmission in different brain regions.
POTENTIAL CLINICAL USES OF mGLUR AGONISTS AND ANTAGONISTS
Because of the ubiquitous distribution of glutamatergic synapses, mGluRs have the potential to participate in a wide variety of functions of the CNS. In addition, because of the wide diversity and heterogeneous distribution of mGluR subtypes, the opportunity exists for developing highly selective drugs that affect a limited number of CNS functions. The mGluRs therefore provide a novel target for development of therepeutic agents that could have a dramatic impact on treatment of a wide variety of psychiatric and neurologic disorders. Importantly, drugs acting at mGluRs would have more subtle effects on transmission at glutamatergic synapses than would iGluR agonists and antagonists and would probably have fewer side effects.
Treatment of Stroke and Neurodegenerative Disorders
One of the most clear potential beneficial effects of mGluR agonists and antagonists is reduction of excitotoxic neuronal damage that occurs after stroke or traumatic brain injury or in certain neurodegenerative disorders. For instance, selective antagonists of mGluR subtypes involved in potentiating responses to activation of iGluRs (see above) could be effective in reducing excitotoxicity, as could agonists at mGluR autoreceptors. Further, the tremendous heterogeneity of mGluR subtypes that serve as autoreceptors at different synapses provides an opportunity for development of drugs that are highly selective for mGluRs in specific brain regions that may be affected in different neurodegenerative disorders. Consistent with a potential neuroprotective effect of mGluR ligands, several studies suggest that agonists of group II and group III mGluRs can be neuroprotective (175) (176) (177) (178) , whereas agonists of group I mGluRs are usually without effect or may potentiate excitotoxicity (100, 178) . The specific roles of different mGluRs in regulating excitotoxicity will likely vary, however, depending on the model and brain region under study.
mGluR Ligands as Cognitive Enhancers
mGluRs play in important role in a number of forms of synaptic plasticity, including induction of hippocampal long-term potentiation (see 179 for review). They also elicit physiologic effects in the hippocampus that might enhance cognitive function (see 180 for review). These data have led to the suggestion that mGluR ligands may be useful as cognitive enhancing agents in patients who have Alzheimer's disease and other memory impairments. Studies of the effects of mGluR ligands on tasks that involve learning and memory in rats are consistent with this hypothesis (181-183). In addition, agonists of group II and group III mGluRs protect cultured neurons against apoptosis induced by β-amyloid peptide (184) , and group I agonists increase breakdown of amyloid precursor protein (185) . Agonists of any of these receptor subtypes therefore have the potential to reduce the progression of Alzheimer's disease.
mGluRs as Targets for Antiepileptic Agents
Activation of mGluRs in the hippocampus has several effects that could facilitate generation of limbic seizures (see 180 for review). Consistent with this, microinjection of 1S, 3R-ACPD into the hippocampus (186) or thalamus (187) results in generalized limbic convulsions in rats, and intracerebroventricular injection of 1S, 3R-ACPD potentiates NMDA-evoked behavioral convulsions (188) . These effects are primarily mediated by group I mGluRs. Interestingly, the seizure-evoking effect of the group I-selective agonists, DHPG, could be attenuated either by mGluR antagonists, or by selective agonists of group II or group III mGluRs (187) . Further, (S)-4C3HPG, an antagonist at group I mGluRs and agonist at group II mGluRs, has anticonvulsant effects in mice (189, 190) . These data suggest that mGluRs may serve as important new targets for development of novel anticonvulsant agents.
Treatment of Movement Disorders
mGluRs may play an important role in various motor circuits, including those in the spinal cord, basal ganglia, and cerebellum (see 180 for review). It has therefore been suggested that mGluR ligands may be useful for treatment of some movement disorders, such as cerebellar ataxia, amyotropic lateral sclerosis, Huntington's chorea, and Parkinson's disease. For instance, intrastriatal injection of mGluR agonists induces motor activation, manifested as contralateral turning, that is mediated by induction of striatal dopamine release (191) . Injection of 1S, 3R-ACPD into the subthalamic nucleus (STN) also induces contralateral turning (192) and induces a Parkinsonian-like rigidity in rats (193) . Drugs selective for mGluRs involved in striatal or STN activation could be useful in treatment of Parkinson's disease.
Treatment of Pain
Studies of the effects of mGluR agonists and antagonists on responses of thalamic (92, 194) and spinal cord neurons (195, 196) to noxious and non-noxious stimuli suggest that mGluRs are preferentially involved in transmitting noxious sensory information in the thalamus and that mGluRs in the spinal cord may be involved in induction of long-term enhancement of responses to noxious stimuli. Selective antagonists for the mGluR subtypes involved in transmitting noxious sensory information could be useful in the treatment of acute and chronic pain.
Treatment of Hypertension
The mGluR agonist 1S, 3R-ACPD directly depolarizes neurons in the NTS and virtually abolishes evoked inhibitory postsynaptic potentials (IPSPs) (see 142, 180 for reviews). This would be expected to elicit cardiovascular responses typical of activation of the baroreceptor reflex. Consistent with this, microinjection of trans-ACPD into the NTS induces a dramatic increase in heart rate and mean arterial pressure (197) . In contrast, activation of mGluRs in raphe obscurus induces a decrease in arterial blood pressure (198) . Thus, antagonists and agonists of mGluRs involved in regulating cardiovascular function in the NTS and raphe obscurus, respectively, could provide novel centrally acting agents for treatment of high blood pressure.
SUMMARY AND CONCLUSIONS
A great deal of progress has been made in isolating and characterizing a family of mGluRs and in determining the physiologic roles of these receptors in mammalian brain. Because of the fundemental roles of mGluRs in a wide variety of neuronal circuits, these studies are having a significant impact on several areas in CNS research. In recent years, a number of mGluR agonists and antagonists have been developed that are selective for specific mGluR subtypes. These compounds provide valuable research tools that are advancing our understanding of mGluRs even further and are providing important insights to mGluR function that are relevant to development of novel treatment strategies for a large number of neurologic and psychiatric disorders. 
